Tech Company Inital Public Offerings
Verve Therapeutics IPO
Verve Therapeutics was acquired by . Shares were listed on 6/17/2021.
Transaction Overview
Company Name
Announced On
6/17/2021
Transaction Type
IPO
Amount
$224,200,000
Proceeds Purpose
Use of proceeds for the Verve Therapeutics IPO are outlined in the company's S1 filing.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
500 Technology Sq. 901
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Not Recorded
Overview
Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary artery disease, the most common type of heart disease and the leading cause of death worldwide.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Burt Adelman
Chief Executive Officer
Sekar Kathiresan
Chief Scientific Officer
Andrew Bellinger
Co-Founder
Keith Joung
Co-Founder
Kiran Musunuru
Co-Founder
Anthony Philippakis
Co-Founder
Issi Rozen
Co-Founder
Barry Ticho
President
Andrew Ashe
Vice President
Kallanthottathil Rajeev
Vice President
Ellen Rohde
VP - Manufacturing
Christopher Cheng
VP - Marketing
Michele Rozen
VP - R & D
Alexandra Chadwick
VP - Regulatory Affairs
Leslie Stolz
Browse more venture capital transactions:
Prev: 6/17/2021: nate venture capital transaction
Next: 6/17/2021: Fractyl Laboratories venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to document all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs